DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Aducanumab is an investigational drug.
There have been 8 clinical trials for Aducanumab. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2015.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognitive Dysfunction, and Dementia. The leading clinical trial sponsors are Biogen and [disabled in preview].
There are four US patents protecting this investigational drug and fifteen international patents.
Recent Clinical Trials for Aducanumab
|A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205||Biogen||Phase 3|
|A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalit||Biogen||Phase 2|
|Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants||Biogen||Phase 1|
Top disease conditions for Aducanumab
Top clinical trial sponsors for Aducanumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Aducanumab||Start Trial||Intranasal administration of guanidinylated aminoglycosides||THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)||Start Trial|
|Aducanumab||Start Trial||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|Aducanumab||Start Trial||Cell culture medium||LA JOLLA BIOLOGICS, INC. (San Diego, CA)||Start Trial|
|Aducanumab||Start Trial||Humanized tau antibodies in alzheimer's disease||Axon Neuroscience SE (Larnaka, CY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Aducanumab||World Intellectual Property Organization (WIPO)||2014159878||2033-03-13||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|